Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.40 |
| ▸ | F2RL1 | P55085 | 3/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL556899 | 0.85 | LMNA (0.39) | HIPK2F2RL1ABL1PDE10A | |
| SCHEMBL5929732 | 0.76 | KDM4E (0.43) | HIPK2F2RL1ALDH1A1 | |
| SCHEMBL300491 | 0.72 | ALOX15 (0.41) | HIPK2F2RL1ALOX15ALDH1A1SMN1; SMN2 | |
| SCHEMBL311710 | 0.71 | BCHE (0.42) | HIPK2F2RL1ALOX15ALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL9200760 | 0.71 | ALOX15 (0.39) | HIPK2F2RL1ALOX15ALDH1A1SMN1; SMN2 | |
| SCHEMBL11585128 | 0.71 | ALOX15 (0.36) | HIPK2ALOX15ALDH1A1SMN1; SMN2 | |
| SCHEMBL6403188 | 0.71 | HIPK2 (0.36) | HIPK2F2RL1ALOX15 | |
| SCHEMBL5891722 | 0.69 | HIPK2 (0.37) | HIPK2ALOX15ALDH1A1SMN1; SMN2 | |
| SCHEMBL3096843 | 0.69 | KDM4E (0.48) | ALOX15ALDH1A1 | |
| Hydrochloric Acid SCHEMBL29375122 | 0.69 | BCHE (0.41) | HIPK2F2RL1ALOX15ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999006-B2 | Anticancer agents; mitogen-activated protein kinases (MEK) | EXELIXIS, INC. (US) | 2011-08-16 | — | — | US | claimed |
| US-20250100966-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | EXELIXIS INC (US) | 2025-03-27 | — | — | US | disclosed |
| US-8859583-B2 | Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2014-10-14 | — | — | US | disclosed |
| US-20120035153-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035153-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, BMX, CDK1 | HIPK2 292/4885F2RL1 2000/4885ALOX15 4640/4885 |
| US-20250100966-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | BRAF, NRAS, KRAS | HIPK2 1508/4885F2RL1 2861/4885ALOX15 1192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.